John K Gillespie

US Patent:

55733441, Nov 12, 1996

Filed:

Oct 17, 1994

Appl. No.:

8/323948

Inventors:

Roger M. Crane - Arnold MD
Douglas C. Loup - Pasadena MD
John W. Gillespie - Hockessin DE
Stephen M. Andersen - Fremont CA
Daniel D. Coppens - Newark DE

Assignee:

The United States of America as represented by the Secretary of the Navy - Washington DC

International Classification:

F16L 1310

US Classification:

403179

Abstract:

A design for a high damping composite joint which dissipates vibrations through the use of air gaps and viscoelastic material minimizing the transfer of vibrations to the metallic coupling. Viscoelastic material is used with adhesive to provide for increased energy dissipation by the joint. As the load increases on the joint, the load transfers from adhesive to the viscoelastic. The viscoelastic begins to take the load of the joint at the point where the adhesive becomes plastic. Acoustic vibrations are then dissipated in the viscoelastic and are prevented from being transferred to the metallic coupling by air gaps provided in the joint. The amount of viscoelastic and adhesive used depends on the anticipated load. Finite element analysis is used to calculate optimal amounts of viscoelastic and adhesive.

US Patent:

20180045730, Feb 15, 2018

Filed:

Jul 21, 2017

Appl. No.:

15/657098

Inventors:

- Rockville MD, US
John Gillespie - Clarksville MD, US
Soon Sik Park - Clarksville MD, US

Assignee:

20/20 GeneSystems, Inc. - Rockville MD

International Classification:

G01N 33/574
A61K 45/06
A61K 31/436
A61K 38/00

Abstract:

A method for identifying cancer patients that are likely to be responders or non-responders to a signal transduction pathway inhibitor is described.

US Patent:

20140378500, Dec 25, 2014

Filed:

Feb 1, 2013

Appl. No.:

14/375827

Inventors:

- Rockville MD, US
John Gillespie - Clarksville MD, US
Soon Sik Park - Clarksville MD, US

Assignee:

20/20 GENE SYSTEMS, INC. - ROCKVILLE MD

International Classification:

G01N 33/574

US Classification:

514291, 435 723

Abstract:

A method for identifying cancer patients that are likely to be responders or non-responders to a signal transduction pathway inhibitor is described.

US Patent:

20140275013, Sep 18, 2014

Filed:

Mar 13, 2014

Appl. No.:

14/209536

Inventors:

Arnab Kumar CHATTERJEE - San Diego CA, US
Fang LIANG - Encinitas CA, US
Casey Jacob Nelson MATHISON - San Diego CA, US
Pranab Kumar MISHRA - West Bengal, IN
Valentina MOLTENI - San Diego CA, US
Advait Suresh Nagle - San Diego CA, US
Frantisek SUPEK - San Diego CA, US
Liying Jocelyn TAN - Singapore, SG
Agnes VIDAL - Spring Valley CA, US
Michael Herman GELB - Seattle WA, US
Frederick Simmons BUCKNER - Seattle WA, US
Hari Babu TATIPAKA - Pradesh, IN
Neil Richard NORCROSS - Dundee, GB
John Robert GILLESPIE - Seattle WA, US

Assignee:

UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION - Seattle WA
IRM LLC - Hamilton

International Classification:

C07D 473/00
C07D 471/04

US Classification:

51421018, 546118, 514303, 544277, 51426323, 544127, 5142342, 544333, 514256, 544362, 51425304, 544105, 5142305, 544238, 51425204

Abstract:

The present invention provides compounds of formula I:or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.